FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1608997557> ?p ?o ?g. }

• W1608997557 endingPage "59" @default.
• W1608997557 startingPage "54" @default.
• W1608997557 abstract "Summary Aim: Highly advanced metastatic bone disease with extensive osseous infiltration of neuroendocrine tumours (NET) may preclude patients from treatment with peptide receptor radionuclide therapy (PRRT) in concern about haematotoxicity. This study aims to assess the safety and efficacy of PRRT with 177Lu-octreotate in a patient cohort with this condition. Patients, methods: 41 PRRT courses were performed in 11 patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET) and florid bone metastases (severely advanced widespread metastatic bone disease). A mean activity of 6.95 GBq 177Lu-octreotate was administered per treatment cycle, aimed at four courses with standard intervals of 3 months. Haematological parameters were determined prior to each treatment course, in 2-4 weeks intervals between the courses, 8-12 weeks after the last course of PRRT and in 3 monthly intervals thereafter. Toxicity was recorded using Common Terminology Criteria for Adverse Events v3.0. Restaging was performed 3 months after termination of PRRT with CT/MRI and functional imaging (modified MDA criteria). Results: Significant (grade III-IV), reversible haematotoxicity occurred in 4 (35%) patients and after 10 (24%) administrations. It either resolved spontaneously (1 patient) or was controlled by supportive measures (3 patients), such as blood transfusions (3 patients) or deferral of the subsequent therapy cycle (1 patient). Patients returned to baseline blood values within up to 23 months after termination of PRRT. The observed treatment response of bone metastases consisted of a partial response in 2, a minor response in 1, stable disease in 7, and progressive disease in 1 patient. Of the 4 patients with metastatic bone pain, 1 experienced complete and 3 partial resolution of symptoms within 3-10 weeks after commencement of PRRT. Conclusion: These preliminary data indicate that PRRT with 177Lu-octreotate can be safely applied even in florid bone metastases with extensive, severely advanced osseous replacement. The higher myelosuppression rate was not associated with serious complications and should not preclude patients from being treated and potentially experiencing remarkable treatment efficacy despite the very advanced stage." @default.
• W1608997557 created "2016-06-24" @default.
• W1608997557 creator A5009302505 @default.
• W1608997557 creator A5046442863 @default.
• W1608997557 creator A5051737896 @default.
• W1608997557 creator A5054631028 @default.
• W1608997557 creator A5061483313 @default.
• W1608997557 creator A5068961348 @default.
• W1608997557 creator A5072823707 @default.
• W1608997557 creator A5077069685 @default.
• W1608997557 creator A5088751597 @default.
• W1608997557 date "2014-01-01" @default.
• W1608997557 modified "2023-09-27" @default.
• W1608997557 title "Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?" @default.
• W1608997557 cites W1973230030 @default.
• W1608997557 cites W1982210666 @default.
• W1608997557 cites W1993872787 @default.
• W1608997557 cites W1995634658 @default.
• W1608997557 cites W2016356824 @default.
• W1608997557 cites W2019607817 @default.
• W1608997557 cites W2020961166 @default.
• W1608997557 cites W2025888580 @default.
• W1608997557 cites W2029425304 @default.
• W1608997557 cites W2063178653 @default.
• W1608997557 cites W2063224036 @default.
• W1608997557 cites W2071433338 @default.
• W1608997557 cites W2074731710 @default.
• W1608997557 cites W2075075102 @default.
• W1608997557 cites W2079633798 @default.
• W1608997557 cites W2092706522 @default.
• W1608997557 cites W2098132980 @default.
• W1608997557 cites W2098468148 @default.
• W1608997557 cites W2102617530 @default.
• W1608997557 cites W2124077899 @default.
• W1608997557 cites W2125398839 @default.
• W1608997557 cites W2135926091 @default.
• W1608997557 cites W2148617171 @default.
• W1608997557 cites W2156664220 @default.
• W1608997557 cites W2306987493 @default.
• W1608997557 doi "https://doi.org/10.3413/nukmed-0614-13-08" @default.
• W1608997557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24777355" @default.
• W1608997557 hasPublicationYear "2014" @default.
• W1608997557 type Work @default.
• W1608997557 sameAs 1608997557 @default.
• W1608997557 citedByCount "29" @default.
• W1608997557 countsByYear W16089975572015 @default.
• W1608997557 countsByYear W16089975572016 @default.
• W1608997557 countsByYear W16089975572017 @default.
• W1608997557 countsByYear W16089975572018 @default.
• W1608997557 countsByYear W16089975572019 @default.
• W1608997557 countsByYear W16089975572020 @default.
• W1608997557 countsByYear W16089975572021 @default.
• W1608997557 countsByYear W16089975572022 @default.
• W1608997557 countsByYear W16089975572023 @default.
• W1608997557 crossrefType "journal-article" @default.
• W1608997557 hasAuthorship W1608997557A5009302505 @default.
• W1608997557 hasAuthorship W1608997557A5046442863 @default.
• W1608997557 hasAuthorship W1608997557A5051737896 @default.
• W1608997557 hasAuthorship W1608997557A5054631028 @default.
• W1608997557 hasAuthorship W1608997557A5061483313 @default.
• W1608997557 hasAuthorship W1608997557A5068961348 @default.
• W1608997557 hasAuthorship W1608997557A5072823707 @default.
• W1608997557 hasAuthorship W1608997557A5077069685 @default.
• W1608997557 hasAuthorship W1608997557A5088751597 @default.
• W1608997557 hasConcept C126322002 @default.
• W1608997557 hasConcept C126838900 @default.
• W1608997557 hasConcept C141071460 @default.
• W1608997557 hasConcept C197934379 @default.
• W1608997557 hasConcept C2777793932 @default.
• W1608997557 hasConcept C2778822529 @default.
• W1608997557 hasConcept C2779066768 @default.
• W1608997557 hasConcept C2779134260 @default.
• W1608997557 hasConcept C2989005 @default.
• W1608997557 hasConcept C2993559085 @default.
• W1608997557 hasConcept C71924100 @default.
• W1608997557 hasConcept C72563966 @default.
• W1608997557 hasConceptScore W1608997557C126322002 @default.
• W1608997557 hasConceptScore W1608997557C126838900 @default.
• W1608997557 hasConceptScore W1608997557C141071460 @default.
• W1608997557 hasConceptScore W1608997557C197934379 @default.
• W1608997557 hasConceptScore W1608997557C2777793932 @default.
• W1608997557 hasConceptScore W1608997557C2778822529 @default.
• W1608997557 hasConceptScore W1608997557C2779066768 @default.
• W1608997557 hasConceptScore W1608997557C2779134260 @default.
• W1608997557 hasConceptScore W1608997557C2989005 @default.
• W1608997557 hasConceptScore W1608997557C2993559085 @default.
• W1608997557 hasConceptScore W1608997557C71924100 @default.
• W1608997557 hasConceptScore W1608997557C72563966 @default.
• W1608997557 hasIssue "02" @default.
• W1608997557 hasLocation W16089975571 @default.
• W1608997557 hasLocation W16089975572 @default.
• W1608997557 hasOpenAccess W1608997557 @default.
• W1608997557 hasPrimaryLocation W16089975571 @default.
• W1608997557 hasRelatedWork W1970326135 @default.
• W1608997557 hasRelatedWork W2099478219 @default.
• W1608997557 hasRelatedWork W2141443930 @default.
• W1608997557 hasRelatedWork W2332637465 @default.
• W1608997557 hasRelatedWork W2933425479 @default.

• next